Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene-Matching trial aims to outsmart cancer by pairing mutations with drugs

NCT ID NCT02534649

Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personalized treatment options. No new drugs are being tested; instead, the focus is on gathering information to improve future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors select more effective, personalized treatments for advanced cancer patients based on their tumor's genetic profile.
What could go wrong
This is an observational profiling study, not a treatment trial. It may not directly improve outcomes, and many patients may not have a targetable alteration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2015

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, 2. Histology: solid malignant tumor or hematological malignancy, 3. Deleted MSA9 4. Deleted MSA9, 5. Deleted MSA9, 6. Deleted MSA9, 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code), 8. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Deleted MSA9 2. Deleted MSA9 3. Deleted MSA9 4. Deleted MSA9 5. Deleted MSA9 6. Deleted MSA9 7. Deleted MSA9 8. Deleted MSA9 9. Individuals deprived of liberty or placed under guardianship 10. Pregnant or breast feeding women, 11. Previous enrolment in the present study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancy Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Eugène Marquis

    ACTIVE_NOT_RECRUITING

    Rennes, France

  • Centre Hospitalier de Pau

    NOT_YET_RECRUITING

    Pau, 64000, France

  • Centre Hospitalier de la Côte Basque

    RECRUITING

    Bayonne, 64000, France

  • Clinique Marzet

    RECRUITING

    Pau, 64000, France

  • Clinique Tivoli-Ducos

    RECRUITING

    Bordeaux, 33000, France

  • Institut Bergonie

    RECRUITING

    Bordeaux, 33076, France

  • Polyclinique Bordeaux Nord Aquitaine

    RECRUITING

    Bordeaux, 33077, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.